GB9904919D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB9904919D0
GB9904919D0 GBGB9904919.9A GB9904919A GB9904919D0 GB 9904919 D0 GB9904919 D0 GB 9904919D0 GB 9904919 A GB9904919 A GB 9904919A GB 9904919 D0 GB9904919 D0 GB 9904919D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
formoterol
solvate
salt
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9904919.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10848904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9904919(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB9904919.9A priority Critical patent/GB9904919D0/en
Publication of GB9904919D0 publication Critical patent/GB9904919D0/en
Priority to PCT/EP2000/001722 priority patent/WO2000051591A1/en
Priority to PL349566A priority patent/PL212355B1/pl
Priority to DK00910739T priority patent/DK1156790T3/da
Priority to IL14435100A priority patent/IL144351A/en
Priority to SI200030170T priority patent/SI1156790T1/xx
Priority to AU32843/00A priority patent/AU770739B2/en
Priority to IDW00200101780A priority patent/ID30171A/id
Priority to JP2000602059A priority patent/JP2002538110A/ja
Priority to CA002362499A priority patent/CA2362499C/en
Priority to KR1020017011162A priority patent/KR100682418B1/ko
Priority to CNB008041911A priority patent/CN1196478C/zh
Priority to RU2001126347/63A priority patent/RU2270670C2/ru
Priority to SK1230-2001A priority patent/SK286338B6/sk
Priority to PT00910739T priority patent/PT1156790E/pt
Priority to BR0008699-1A priority patent/BR0008699A/pt
Priority to AT00910739T priority patent/ATE241970T1/de
Priority to CZ20013168A priority patent/CZ294089B6/cs
Priority to HK02103183.9A priority patent/HK1043048B/en
Priority to NZ513742A priority patent/NZ513742A/en
Priority to DE60003160T priority patent/DE60003160T2/de
Priority to EP03003950A priority patent/EP1325765A1/en
Priority to HU0200142A priority patent/HU229073B1/hu
Priority to EP00910739A priority patent/EP1156790B1/en
Priority to ES00910739T priority patent/ES2200837T3/es
Priority to ZA200106442A priority patent/ZA200106442B/en
Priority to NO20013988A priority patent/NO331428B1/no
Priority to US09/942,805 priority patent/US20020055494A1/en
Priority to US10/262,408 priority patent/US20030050290A1/en
Priority to US10/718,316 priority patent/US7067502B2/en
Priority to CL200401170A priority patent/CL2004001170A1/es
Priority to US11/199,291 priority patent/US7566705B2/en
Priority to JP2009174025A priority patent/JP5646828B2/ja
Priority to JP2013010543A priority patent/JP5663046B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB9904919.9A 1999-03-03 1999-03-03 Organic compounds Ceased GB9904919D0 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
GBGB9904919.9A GB9904919D0 (en) 1999-03-03 1999-03-03 Organic compounds
EP00910739A EP1156790B1 (en) 1999-03-03 2000-03-01 Combinations of formoterol and mometasone furoate
ES00910739T ES2200837T3 (es) 1999-03-03 2000-03-01 Combinaciones de formoterol y furoato de mometasona.
BR0008699-1A BR0008699A (pt) 1999-03-03 2000-03-01 Combinações de formoterol e furoato demometasona para asma
HK02103183.9A HK1043048B (en) 1999-03-03 2000-03-01 Combination of formoterol and mometasone fumarate
DK00910739T DK1156790T3 (da) 1999-03-03 2000-03-01 Kombinationer af formoterol og motetason furat
IL14435100A IL144351A (en) 1999-03-03 2000-03-01 A combination of formoterol and momatasone furoat for the treatment of asthma
SI200030170T SI1156790T1 (en) 1999-03-03 2000-03-01 Combinations of formoterol and mometasone furoate
AU32843/00A AU770739B2 (en) 1999-03-03 2000-03-01 Combinations of formoterol and mometasone furoate for asthma
IDW00200101780A ID30171A (id) 1999-03-03 2000-03-01 Kombinasi formoterol dan mometason furoat untuk asma
JP2000602059A JP2002538110A (ja) 1999-03-03 2000-03-01 喘息用のフォルモテロールおよびモメタゾンフロエートの組合せ
CA002362499A CA2362499C (en) 1999-03-03 2000-03-01 Combinations of formoterol and mometasone furoate for asthma
KR1020017011162A KR100682418B1 (ko) 1999-03-03 2000-03-01 천식용 포르모테롤 및 모메타손 푸로에이트의 조합물
CNB008041911A CN1196478C (zh) 1999-03-03 2000-03-01 用于治疗气喘的福莫特罗和糖酸莫米松的组合
RU2001126347/63A RU2270670C2 (ru) 1999-03-03 2000-03-01 Лекарственное средство и фармацевтический набор, предназначенные для лечения астмы
SK1230-2001A SK286338B6 (en) 1999-03-03 2000-03-01 Medicament containing formoterol and mometasone fuorate in the treatment of inflammatory or obstructive airways diseases
PT00910739T PT1156790E (pt) 1999-03-03 2000-03-01 Combinacoes de formoterol e furoato de mometasona para a asma
PCT/EP2000/001722 WO2000051591A1 (en) 1999-03-03 2000-03-01 Combinations of formoterol and mometasone furoate for asthma
AT00910739T ATE241970T1 (de) 1999-03-03 2000-03-01 Kombinationen von formoterol und mometasonfuroat
CZ20013168A CZ294089B6 (cs) 1999-03-03 2000-03-01 Kombinovaný prostředek formoterolu a mometasonfuroátu pro léčbu astmatu
PL349566A PL212355B1 (pl) 1999-03-03 2000-03-01 Kombinacja farmaceutyczna zawierajaca formoterol i pirosluzan mometazonu, jej zastosowanie oraz zestaw farmaceutyczny
NZ513742A NZ513742A (en) 1999-03-03 2000-03-01 Combinations of formoterol and mometasone furoate for asthma
DE60003160T DE60003160T2 (de) 1999-03-03 2000-03-01 Kombinationen von formoterol und mometasonfuroat
EP03003950A EP1325765A1 (en) 1999-03-03 2000-03-01 Combinations of Formoterol and Mometasone Furoate for Asthma
HU0200142A HU229073B1 (en) 1999-03-03 2000-03-01 Combinations of formoterol and mometasone furoate for asthma
ZA200106442A ZA200106442B (en) 1999-03-03 2001-08-06 Combinations of formoterol and mometasone furoate for asthma.
NO20013988A NO331428B1 (no) 1999-03-03 2001-08-16 Medikament som inneholder kombinasjoner av formoterol og mometasonfuroat mot luftveissykdom, og anvendelse av formoterol og mometasonfuroat for fremstilling av nevnte medikament
US09/942,805 US20020055494A1 (en) 1999-03-03 2001-08-30 Combinations of formoterol and mometasone furoate for asthma
US10/262,408 US20030050290A1 (en) 1999-03-03 2002-10-01 Combination of formoterol and mometasone furoate for asthma
US10/718,316 US7067502B2 (en) 1999-03-03 2003-11-20 Combinations of formoterol and mometasone furoate for asthma
CL200401170A CL2004001170A1 (es) 1999-03-03 2004-05-20 Combinacion farmaceutica inhalable que contiene (a) formoterol, o una sal, o un solvato de el o de la sal y (b) furoato de mometasona; estuche farmaceutico que la comprende; y su uso en la terapia de una enfermedad inflamatoria u obstructiva de las v
US11/199,291 US7566705B2 (en) 1999-03-03 2005-08-08 Combination of formoterol and mometasone furoate for asthma
JP2009174025A JP5646828B2 (ja) 1999-03-03 2009-07-27 喘息用のフォルモテロールおよびモメタゾンフロエートの組合せ
JP2013010543A JP5663046B2 (ja) 1999-03-03 2013-01-23 喘息用のフォルモテロールおよびモメタゾンフロエートの組合せ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9904919.9A GB9904919D0 (en) 1999-03-03 1999-03-03 Organic compounds

Publications (1)

Publication Number Publication Date
GB9904919D0 true GB9904919D0 (en) 1999-04-28

Family

ID=10848904

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9904919.9A Ceased GB9904919D0 (en) 1999-03-03 1999-03-03 Organic compounds

Country Status (27)

Country Link
US (4) US20020055494A1 (https=)
EP (2) EP1325765A1 (https=)
JP (3) JP2002538110A (https=)
KR (1) KR100682418B1 (https=)
CN (1) CN1196478C (https=)
AT (1) ATE241970T1 (https=)
AU (1) AU770739B2 (https=)
BR (1) BR0008699A (https=)
CA (1) CA2362499C (https=)
CL (1) CL2004001170A1 (https=)
CZ (1) CZ294089B6 (https=)
DE (1) DE60003160T2 (https=)
DK (1) DK1156790T3 (https=)
ES (1) ES2200837T3 (https=)
GB (1) GB9904919D0 (https=)
HK (1) HK1043048B (https=)
HU (1) HU229073B1 (https=)
ID (1) ID30171A (https=)
IL (1) IL144351A (https=)
NO (1) NO331428B1 (https=)
NZ (1) NZ513742A (https=)
PL (1) PL212355B1 (https=)
PT (1) PT1156790E (https=)
RU (1) RU2270670C2 (https=)
SK (1) SK286338B6 (https=)
WO (1) WO2000051591A1 (https=)
ZA (1) ZA200106442B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
EP3384931B1 (en) * 2002-03-01 2019-07-24 Chiesi Farmaceutici S.p.A. Formoterol superfine formulation
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
DK1542904T3 (da) * 2002-08-27 2008-04-21 Schering Corp Fremgangsmåde til fremstilling af formuleringer til en inhalator med målte doser
US20040043064A1 (en) * 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
KR20060106823A (ko) * 2003-10-20 2006-10-12 쉐링 코포레이션 약제학적 에어로졸 조성물
EP1680084A2 (en) * 2003-10-21 2006-07-19 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
EP2484382A1 (en) * 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
WO2007059620A1 (en) * 2005-11-23 2007-05-31 Feanny Stephen J Method for administering formoterol using a nebulizer
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
US20080294720A1 (en) * 2007-05-21 2008-11-27 International Business Machines Corporation Enhanced Online Collaboration System
US8898316B2 (en) * 2007-05-30 2014-11-25 International Business Machines Corporation Enhanced online collaboration system for viewers of video presentations
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011093815A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
US20130177651A1 (en) * 2010-09-03 2013-07-11 Pharmaterials Limited Pharmaceutical Composition Suitable for Use in a Dry Powder Inhaler
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
KR102449403B1 (ko) * 2014-10-08 2022-09-29 잠본쏘시에떼퍼아찌오니 부데소니드 및 포르모테롤을 함유하는 약학 조성물
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3556348B1 (en) 2015-12-04 2021-02-03 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CN115813935A (zh) * 2021-09-16 2023-03-21 上海上药信谊药厂有限公司 药物组合物、气雾剂及其制备方法和气雾剂产生系统
CN116763797B (zh) * 2022-03-09 2025-09-02 上海医药工业研究院有限公司 一种药物组合微球、其制备方法及其原料组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
ES2172510T3 (es) 1991-12-18 2002-10-01 Astrazeneca Ab Nueva combinacion de formoterol y budesonida.
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
EP0806940B1 (en) 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
AU718967B2 (en) * 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
DK0969816T3 (da) * 1997-03-20 2005-03-14 Schering Corp Fremstilling af pulveragglomerater
EP1033991B1 (en) * 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma

Also Published As

Publication number Publication date
NO20013988L (no) 2001-08-16
CZ20013168A3 (cs) 2001-12-12
PL212355B1 (pl) 2012-09-28
DE60003160D1 (de) 2003-07-10
US7566705B2 (en) 2009-07-28
JP2013067668A (ja) 2013-04-18
JP2002538110A (ja) 2002-11-12
BR0008699A (pt) 2001-12-26
ID30171A (id) 2001-11-08
SK286338B6 (en) 2008-07-07
CN1341017A (zh) 2002-03-20
AU770739B2 (en) 2004-03-04
KR20010102473A (ko) 2001-11-15
US7067502B2 (en) 2006-06-27
KR100682418B1 (ko) 2007-02-15
JP2010001295A (ja) 2010-01-07
CA2362499C (en) 2009-01-27
US20030050290A1 (en) 2003-03-13
ZA200106442B (en) 2002-09-05
CL2004001170A1 (es) 2005-03-28
DE60003160T2 (de) 2004-05-19
PT1156790E (pt) 2003-10-31
JP5663046B2 (ja) 2015-02-04
ATE241970T1 (de) 2003-06-15
IL144351A0 (en) 2002-05-23
US20040105822A1 (en) 2004-06-03
CZ294089B6 (cs) 2004-10-13
EP1156790B1 (en) 2003-06-04
HK1043048A1 (en) 2002-09-06
NO20013988D0 (no) 2001-08-16
CN1196478C (zh) 2005-04-13
DK1156790T3 (da) 2003-09-29
HK1043048B (en) 2004-01-30
JP5646828B2 (ja) 2014-12-24
HU229073B1 (en) 2013-07-29
EP1156790A1 (en) 2001-11-28
SK12302001A3 (sk) 2001-12-03
AU3284300A (en) 2000-09-21
NO331428B1 (no) 2011-12-27
NZ513742A (en) 2001-09-28
US20020055494A1 (en) 2002-05-09
EP1325765A1 (en) 2003-07-09
HUP0200142A2 (en) 2002-06-29
CA2362499A1 (en) 2000-09-08
ES2200837T3 (es) 2004-03-16
WO2000051591A1 (en) 2000-09-08
US20060009437A1 (en) 2006-01-12
RU2270670C2 (ru) 2006-02-27
IL144351A (en) 2005-12-18

Similar Documents

Publication Publication Date Title
GB9904919D0 (en) Organic compounds
GB9902689D0 (en) Organic compounds
GB0029562D0 (en) Organic compounds
MY126768A (en) Combinations of formoterol and fluticasone propionate for asthma
DE60019167D1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
EP1663220A4 (en) PROCESS, SALTS, COMPOSITIONS AND USE
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
WO2004037199A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
CA2370501A1 (en) Pharmaceutical composition for the therapy of lower urinary tract symptoms
ATE286716T1 (de) Pharmazeutische formulierungen enthaltend salmeterol

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)